Evidence map of clinical research on Chinese patent medicines for post-acute myocardial infarction heart failure
An evidence map was established to comprehensively sort out the clinical research in the treatment of post-acute myocar-dial infarction heart failure(P-AMI-HF)with Chinese patent medicines,so as to reveal the distribution of evidence in this field.CNKI,Wanfang,VIP,SinoMed,PubMed,Cochrane Library,and EMbase were searched for the randomized controlled trial(RCT),systematic reviews/Meta-analysis,and guidelines/consensus in this field.The evidence was analyzed and displayed in the form of a combination of text,charts,bubble charts,and bar charts,and the quality of RCT,systematic reviews/Meta-analysis,and guidelines/consensus were evaluated by RoB 1.0,AMSTAR2,and AGREE Ⅱ,respectively.A total of 163 RCTs,4 systematic reviews/Meta-analysis,1 network Meta-analysis,2 observational studies,and 5 guidelines/consensus were included.In recent years,the total num-ber of publications in this field has shown an upward trend.There were a variety of Chinese patent medicines in the treatment of P-AMI-HF,among which Shenfu Injection received the most attention.The clinical RCT and systematic reviews/Meta-analysis general-ly had poor quality,and the RCT mostly had a small size,a single center,and a short cycle.The outcome indicators mainly included cardiac function indicators,myocardial injury markers,total response rate,hemodynamic indicators,and safety indicators,while the characteristic efficacy indicators of TCM received insufficient attention.The development processes of some guidelines/consensus lack standardization,which compromised their authority and rationality.Chinese patent medicines have advantages in the treatment of P-AMI-HF,while there are also problems,which remain to be solved by more high-quality evidence.That is,more large-sample and multi-center clinical studies should be carried out in the future,and the formulation process of relevant systematic reviews/Meta-analy-sis and guideline/consensus should be standardized and the quality of evidence should be improved.In this way,the effectiveness and safety of Chinese patent medicines in the treatment of P-AMI-HF can be explored.
Chinese patent medicinemyocardial infarctionheart failurerandomized controlled trialevidence mapsystematic review
NETL
NSTL
万方数据
